Next Article in Journal
Structure Elucidation and Functional Studies of a Novel β-hairpin Antimicrobial Peptide from the Marine Polychaeta Capitella teleta
Next Article in Special Issue
The Diversity, Metabolomics Profiling, and the Pharmacological Potential of Actinomycetes Isolated from the Estremadura Spur Pockmarks (Portugal)
Previous Article in Journal
Efficient Purification of R-phycoerythrin from Marine Algae (Porphyra yezoensis) Based on a Deep Eutectic Solvents Aqueous Two-Phase System

Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes

Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, 90123 Palermo, Italy
Faculty of Biomedical Sciences, Institute of Oncology Research, USI, 6500 Bellinzona, Switzerland
Instituto de Productos Naturales y Agrobiología (IPNA-CSIC), La Laguna, 38206 Tenerife, Spain
Instituto Universitario de Bio-Orgánica Antonio González (IUBO AG), Universidad de La Laguna (ULL), La Laguna, 38200 Tenerife, Spain
Department of Bioengineering, Faculty of Engineering, Manisa Celal Bayar University, 45119 Manisa, Turkey
Research Center for Testing and Analysis (EGE MATAL), Ege University Application, 35100 İzmir, Turkey
Department of Biology, Faculty of Science, University of Sarajevo, 71000 Sarajevo, Bosnia and Herzegovina
Marine Natural Products Team, UMR 7272, Institut de Chimie de Nice, Université Côte d’Azur, CNRS, 06108 Nice, France
Faculty of Biomedical Sciences, USI, 6900 Lugano, Switzerland
Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, 1200 Vienna, Austria
Marine Biology Station Piran, National Institute of Biology, 1000 Ljubljana, Slovenia
Marine Biodiscovery Laboratory, School of Chemistry and Ryan Institute, National University of Ireland, Galway (NUI Galway), H91TK33 Galway, Ireland
UCIBIO—Applied Biomolecular Sciences Unit, Department of Chemistry, Blue Biotechnology & Biomedicine Lab, Faculty of Science and Technology, NOVA University of Lisbon, 2829-516 Caparica, Portugal
Oncology Institute of Southern Switzerland, 6500 Bellinzona, Switzerland
Authors to whom correspondence should be addressed.
Mar. Drugs 2020, 18(12), 619;
Received: 16 November 2020 / Revised: 30 November 2020 / Accepted: 2 December 2020 / Published: 4 December 2020
(This article belongs to the Collection Ocean4Biotech)
The marine environment is a rich source of biologically active molecules for the treatment of human diseases, especially cancer. The adaptation to unique environmental conditions led marine organisms to evolve different pathways than their terrestrial counterparts, thus producing unique chemicals with a broad diversity and complexity. So far, more than 36,000 compounds have been isolated from marine micro- and macro-organisms including but not limited to fungi, bacteria, microalgae, macroalgae, sponges, corals, mollusks and tunicates, with hundreds of new marine natural products (MNPs) being discovered every year. Marine-based pharmaceuticals have started to impact modern pharmacology and different anti-cancer drugs derived from marine compounds have been approved for clinical use, such as: cytarabine, vidarabine, nelarabine (prodrug of ara-G), fludarabine phosphate (pro-drug of ara-A), trabectedin, eribulin mesylate, brentuximab vedotin, polatuzumab vedotin, enfortumab vedotin, belantamab mafodotin, plitidepsin, and lurbinectedin. This review focuses on the bioactive molecules derived from the marine environment with anticancer activity, discussing their families, origin, structural features and therapeutic use. View Full-Text
Keywords: marine natural products; marine drugs; anticancer; drug discovery; clinical pipeline marine natural products; marine drugs; anticancer; drug discovery; clinical pipeline
Show Figures

Figure 1

MDPI and ACS Style

Barreca, M.; Spanò, V.; Montalbano, A.; Cueto, M.; Díaz Marrero, A.R.; Deniz, I.; Erdoğan, A.; Lukić Bilela, L.; Moulin, C.; Taffin-de-Givenchy, E.; Spriano, F.; Perale, G.; Mehiri, M.; Rotter, A.; P. Thomas, O.; Barraja, P.; Gaudêncio, S.P.; Bertoni, F. Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes. Mar. Drugs 2020, 18, 619.

AMA Style

Barreca M, Spanò V, Montalbano A, Cueto M, Díaz Marrero AR, Deniz I, Erdoğan A, Lukić Bilela L, Moulin C, Taffin-de-Givenchy E, Spriano F, Perale G, Mehiri M, Rotter A, P. Thomas O, Barraja P, Gaudêncio SP, Bertoni F. Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes. Marine Drugs. 2020; 18(12):619.

Chicago/Turabian Style

Barreca, Marilia, Virginia Spanò, Alessandra Montalbano, Mercedes Cueto, Ana R. Díaz Marrero, Irem Deniz, Ayşegül Erdoğan, Lada Lukić Bilela, Corentin Moulin, Elisabeth Taffin-de-Givenchy, Filippo Spriano, Giuseppe Perale, Mohamed Mehiri, Ana Rotter, Olivier P. Thomas, Paola Barraja, Susana P. Gaudêncio, and Francesco Bertoni. 2020. "Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes" Marine Drugs 18, no. 12: 619.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop